| Authors: |
Schoenfeld AJ; Division of Solid Tumor Oncology, Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York., Lee SM; Clinical Research Division, Department of Medicine, Fred Hutchinson Cancer Center, Seattle, Washington., Doger de Spéville B; TART Madrid-FJD, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain., Gettinger SN; Division of Medical Oncology, Department of Medicine, Yale Cancer Center, North Haven, Connecticut., Häfliger S; Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Sukari A; Department of Oncology, Barbara Ann Karmanos Cancer Hospital, Detroit, Michigan., Papa S; School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom.; Department of Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom., Rodríguez-Moreno JF; Department of Medical Oncology, Hospital Universitario HM Sanchinarro, Centro Integral Oncológico Clara Campal, Madrid, Spain., Graf Finckenstein F; Iovance Biotherapeutics, Inc., San Carlos, California., Fiaz R; Iovance Biotherapeutics, Inc., San Carlos, California., Catlett M; Iovance Biotherapeutics, Inc., San Carlos, California., Chen G; Iovance Biotherapeutics, Inc., San Carlos, California., Qi R; Iovance Biotherapeutics, Inc., San Carlos, California., Masteller EL; Iovance Biotherapeutics, Inc., San Carlos, California., Gontcharova V; Iovance Biotherapeutics, Inc., San Carlos, California., He K; Division of Medical Oncology, Department of Internal Medicine, Thoracic Oncology Program, Ohio State University, Columbus, Ohio. |
